The latest report Huntington’s Disease Pipeline Highlights – 2014, provides most up-to-date information on key pipeline molecules in the global huntington’s disease market. It covers emerging therapies for huntington’s disease in active clinical development stages including early and late stage clinical trials. The pipeline data presented in this report helps executives for tracking competition, identifying partners, evaluating opportunities, formulating business development strategies, and executing in-licensing and out-licensing deals.
Clinical Trial Stages:
The report provides huntington’s disease pipeline molecules by clinical trial stages including both early and late stage development – phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.
Drug Mechanism Classes:
The report provides huntington’s disease pipeline molecules by their dominant mechanism of action. This helps executives categorize molecules based on their drug class and also assess the strengths and weaknesses of compounds.
The report provides huntington’s disease pipeline molecules by the Originator Company.